What is the recommended dosing of Nexium (esomeprazole) for infants 1‑month‑old to 12‑months‑old weighing ≥3 kg with normal renal and hepatic function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 6, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Nexium (Esomeprazole) Dosing for Infants 1-12 Months Old

For infants aged 1-11 months weighing ≥3 kg with GERD, esomeprazole should be dosed at 1.0 mg/kg once daily, based on FDA-approved weight-based dosing that has demonstrated effective acid suppression and tolerability in this age group. 1

Weight-Based Dosing Algorithm

For infants 1-11 months old:

  • Dose: 1.0 mg/kg once daily 1
  • This dosing achieves therapeutic drug exposure (AUC and Cmax) comparable to effective adult doses 1
  • Pharmacokinetic studies demonstrate dose-proportional exposure related to both weight and age in this population 1

Practical Dosing Examples

For a typical infant weight range:

  • 5 kg infant: 5 mg once daily
  • 7 kg infant: 7 mg once daily
  • 10 kg infant: 10 mg once daily

The commercially available esomeprazole granules can be mixed with water or administered via nasogastric tube if needed 1.

Clinical Efficacy Evidence

Treatment duration and expected outcomes:

  • In infants with erosive esophagitis, 8 weeks of esomeprazole treatment resulted in 89% erosion resolution 2
  • For symptomatic GERD in infants 1-11 months, esomeprazole demonstrated significant symptom improvement compared to placebo in post-hoc analysis 3
  • Weight-adjusted doses of 2.5-10 mg once daily were well-tolerated during clinical trials 3

Important Clinical Considerations

Diagnostic challenges in this age group:

  • The distinction between physiologic reflux and GERD requiring treatment remains controversial in infants 3, 4
  • Improved diagnostic criteria are needed to identify which infants truly benefit from acid suppression therapy 3
  • Consider endoscopic or histologic confirmation when feasible, as infants with documented erosive esophagitis show clearer treatment benefit 3

Safety profile:

  • Esomeprazole was well-tolerated in clinical trials of infants 1-11 months old 3, 1
  • Serious adverse events in pediatric studies were generally unrelated to treatment 1
  • The very low-certainty evidence base means long-term safety data remain limited 4

Critical Pitfall to Avoid

Do not extrapolate dosing for infants <1 month old from the 1-11 month dosing. Neonates 0-1 month require a lower dose of 0.5 mg/kg once daily due to immature drug clearance mechanisms 1. Using the higher 1.0 mg/kg dose in neonates could result in excessive drug exposure.

When to Reconsider Treatment

If symptoms do not improve after 2 weeks of appropriate dosing, reassess the diagnosis—many infants have physiologic reflux that does not require pharmacologic intervention 3. Non-pharmacologic interventions and parental reassurance should be attempted first in most cases, reserving esomeprazole for infants with documented erosive disease or severe symptoms unresponsive to conservative management 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.